Siemens Healthineers announced this week that Jane Kilkenny will be the company’s new vice president of U.S. magnetic resonance (MR) business management.

The U.S. Department of Veteran’s Affairs inspector general is auditing mass cancellations at eight VA medical centers across the country to determine if the VA processed and managed radiology requests in a timely and appropriate manner since 2016, USA Today reported on Oct. 1.

Multiple patient and provider groups have joined the American College of Radiology (ACR) in a call on Congress to pass the CT Colonography Screening for Colorectal Cancer Act (S.3456/H.R. 1298), according to an ACR release.

In the latest in an international trade war, China has imposed $60 billion in tariffs on imported U.S. goods on Monday, Sept. 17, in retaliation against President Donald Trump imposing $200 billion worth in tariffs on Chinese imported goods—including medical imaging equipment and other healthcare technologies, NPR reports.

Patients with high-deductible health plans (HDHPs) continue to see out-of-pocket costs rise. Despite this, healthcare prices remain largely a mystery to consumers—but what if a hospital helped families better understand their potential out-of-pocket expenses?

On Monday, Sept. 17, Indianapolis-based TriMedx announced plans to buy the healthcare technologies division of Aramark Corporation for $300 million. The two companies have signed a definitive agreement and expect the transaction to be completed by the end of the year.

Roughly 30 U.S. senators and congressional representatives were sought to cosponsor the CT Colonography Screening for Colorectal Cancer Act of 2017—H.R. 1298—at a Capitol Hill briefing on Wednesday, Sept. 12. The meeting was sponsored by the American College of Radiology (ACR) and the Colorectal Cancer Alliance, according to an ACR press release.

Despite national guidelines advising against prostate cancer screening in men 70 or older, researchers from the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center found that prostate cancer care for this demographic costs Medicare more than $400 million a year, according to a study published Sept. 13 in JAMA Oncology.